Drug Detail
Information about MEK162 + BYL719
Generic Name |
||
|---|---|---|
IND |
MEK162 + BYL719 | |
Brand Name (US) |
||
Manufacturer |
Novartis | |
Drug Type |
Kinase inhibitor | |
Delivery |
Oral | |
Approval Status |
Phase 1 | |
Indications |
||
Overall Strategy |
Oncogenic Signal Path Based | |
Strategy |
Block KIT Signal Path | |
Drug Category |
PI3K inhibitor + MEK inhibitor | |
Search for this drug/combination in: